SCHEMBL30195073

SCHEMBL30195073

Nc1ncnc2c1ncn2[C@]1(F)O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 5/20 0.59
P2RY2 P41231 3/20 0.59
SRC P12931 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
DNPH1 O43598 1/20 0.59
PRKAB2 O43741 1/20 0.59
TRPM2 O94759 1/20 0.59
LDHA P00338 1/20 0.59
ADRB2 P07550 1/20 0.59
FBP1 P09467 1/20 0.59
ADORA1 P30542 1/20 0.59
PRKAG1 P54619 1/20 0.59
PRKAA2 P54646 1/20 0.59
PDE4D Q08499 1/20 0.59
KCNH2 Q12809 1/20 0.59
PRKAA1 Q13131 1/20 0.59
PDE3A Q14432 1/20 0.59
TAS1R3 Q7RTX0 1/20 0.59
TAS1R1 Q7RTX1 1/20 0.59
P2RY11 Q96G91 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2791981 1.00 P2RY1 (0.59) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL10824472 0.87 P2RY1 (0.60) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL28769844 0.86 P2RY1 (0.57) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL214972 0.86 P2RY1 (0.59) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL16108838 0.86 P2RY1 (0.59) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL474415 0.85 P2RY1 (0.56) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL16700549 0.85 P2RY1 (0.58) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL29959063 0.84 P2RX1 (0.58) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL6712740 0.83 P2RY1 (0.56) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL1299343 0.83 P2RY1 (0.58) P2RY1P2RY2SRCSMN1; SMN2DNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122505-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE BANK OF AMERICA, N.A. 2025-04-17 US disclosed
US-20230026968-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026968-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE AARS1, RNASE1, DDX39B P2RY1 4802/4885P2RY2 4793/4885SRC 4676/4885
US-20250122505-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE AARS1, RNASE1, DDX39B P2RY1 4802/4885P2RY2 4793/4885SRC 4676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.